💊 UK’s NICE approves a $3 billion treatment; More bad news for Biogen; Cipla acquires more green energy stakes; Is Sanofi’s $11 billion bet beginning to pay off?

Hello and welcome to another exciting week. Wait, you don’t think the week’s going to be exciting? Then you need this. 

In today’s issue of The Kable: Good news for Sanofi; Bad news for Gilead; The US FDA gets busy; A new call for proposals from CEPI; Disposable gastroscopes and more. Much more. Also, you may notice we’ve added sources for every story, j…